In this context relevant, CAV1 and CD59 are present together with delta-catenin in urinary EVs of prostate cancer patients, whereby delta-catenin was shown to be released to the extracellular matrix thanks to the presence of CAV1 and CD59 [174,175]. The gene discussed is CD59; the disease is prostate cancer.